Sp1 高表达与脑膜瘤复发相关。
High Expression of Sp1 is Associated with Recurrence of Meningioma.
机构信息
Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Surgery, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
出版信息
World Neurosurg. 2021 May;149:e1056-e1060. doi: 10.1016/j.wneu.2021.01.016. Epub 2021 Jan 13.
BACKGROUND
Meningioma has the second highest incidence among primary intracranial tumors. There is no effective treatment or targeted therapy for meningioma except excision and radiotherapy. Sp1 (specificity protein 1) is a transcription factor that regulates tumor growth, but the literature describing the relationship between Sp1 and meningioma is scarce. The purpose of this study was to investigate the relationship between Sp1 expression and the clinicopathological parameters in meningioma by immunohistochemical staining.
METHODS
We collected samples from 74 patients from 2008-2012 in Kaohsiung Medical University Hospital, with staging and prognosis of the pathological section of the meningioma.
RESULTS
Our results show that Sp1 expression was significantly associated with World Health Organization grade, malignancy, and recurrence in patients with meningioma.
CONCLUSIONS
High expression of Sp1 in patients with meningioma was linked to poor prognosis of recurrence-free time. Therefore Sp1 may be a candidate biomarker of prognosis and therapy target in meningioma.
背景
脑膜瘤是原发性颅内肿瘤中发病率第二高的肿瘤。除了切除和放疗之外，脑膜瘤没有有效的治疗方法或靶向治疗。Sp1（特异性蛋白 1）是一种调节肿瘤生长的转录因子，但描述 Sp1 与脑膜瘤之间关系的文献很少。本研究旨在通过免疫组织化学染色研究 Sp1 表达与脑膜瘤临床病理参数之间的关系。
方法
我们收集了 2008 年至 2012 年间高雄医学大学附属医院 74 名患者的样本，对脑膜瘤的病理切片进行了分期和预后评估。
结果
我们的结果表明，Sp1 表达与脑膜瘤患者的世界卫生组织分级、恶性程度和复发显著相关。
结论
脑膜瘤患者中 Sp1 的高表达与无复发生存时间的不良预后相关。因此，Sp1 可能是脑膜瘤预后和治疗靶点的候选生物标志物。
Zotero 插件